According to the regulatory filing, the inspection was conducted at the subsidiary’s manufacturing facility located in Sancham Village, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh, from June 22 to June 26.
The facility manufactures Active Pharmaceutical Ingredients (API) and pharmaceutical formulation intermediates.
The company stated that the inspection concluded with two observations. Aurobindo Pharma said the observations would be addressed and responded to within the stipulated timeline.
In its disclosure, the company added that there is no impact on its financials or operations arising from the inspection outcome.
The filing was submitted to both the National Stock Exchange of India (NSE) and BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Aurobindo Pharma said it remains committed to maintaining high quality manufacturing standards and would keep the stock exchanges informed of any further developments related to the matter.
ALSO READ | SpaceX to join Nasdaq 100 on July 7, may spur passive fund inflows
